Drug Trial Radar · NCT07804303
Bioequivalence Study of Budesonide/Formoterol Inhalation Powder in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jan 13, 2024
Primary completion
Jan 22, 2024
Study completion Jan 24, 2024
Sponsor
- Lead sponsor
- Shanghai Xin Huanghe Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this study is to learn if a new formulation of Budesonide/Formoterol Inhalation Powder (160μg/4.5μg), manufactured by Shanghai New Huanghe Pharmaceutical Co., Ltd., works the same as the already approved reference product, Symbicort® Turbuhaler® (160μg/4.5μg), in the body. It will also learn about the safety of the new formulation. The main questions it aims to answer are: * How quickly and how much of the study drug gets into the blood after inhalation, compared with the reference product? * What medical problems do participants have when taking the study drug? Researchers will compare the new formulation to the reference product (the already approved treatment) to see if they are bioequivalent. Participants will: * Be randomly assigned to receive either the new formulation or the reference product in the first period, then switch to the other in the second period * Take a single dose of 2 inhalations in each period, with a 4-day washout period between doses * Have 22 blood samples collected over 36 hours after each dose to measure drug levels in the blood * Visit the clinic for checkups, including vital signs, physical examinations, and laboratory tests * Be monitored for any side effects throughout the study
Conditions
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Test)Drug
160 μg/4.5 μg, administered as 2 inhalations, manufactured by Shanghai New Huanghe Pharmaceutical Co., Ltd.
Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Reference)Drug
160 μg/4.5 μg, administered as 2 inhalations, manufactured by AstraZeneca AB.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Concentration (Cmax)Time frame: 0 to 36 hours post-dose in each period
- Area Under the Plasma Concentration-Time Curve from Time 0 to the Last Measurable Concentration (AUC0-t)Time frame: 0 to 36 hours post-dose in each period
- Area Under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-∞)Time frame: 0 to 36 hours post-dose in each period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing Gaoxin Hospital
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.